Radiopharm Theranostics Limited (RADX) Stock Price & Analysis
Radiopharm Theranostics Limited (RADX) closed at USD 1.08 on Thursday, October 15, 2026, down 3.57% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.12; the Oct 15, 2026 session ranged USD 1.01–1.15 on volume of 65,876 shares. Market capitalization is $15.76M, with a 52-week range of USD 1–16.25 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RADX.md
Key facts (RADX)
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 16.95 (range 12.41–29.94).
- Total return with dividends: 1Y -84.8% vs S&P 500 +18.1%; 5Y -94.3% vs S&P 500 +85.1%.
Analysts (RADX)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 16.95 (low 12.41, high 29.94).
Total return (dividends reinvested) (RADX)
| 1Y (from 2025-10-16) | 5Y (from 2024-12-02) | |
|---|---|---|
| Total return | -84.8% | -94.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -84.9% | -78.4% |
| Volatility (annualized) | 129.8% | 110.6% |
| Max drawdown | -89.8% (Dec 2025→Oct 2026) | -94.3% (Dec 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 1.08 |
|---|---|
| Change | ▼ 3.57% (down) |
| Previous Close | USD 1.12 |
| Open | USD 1.12 |
| Day Range | USD 1.01 – 1.15 |
| 52-Week Range | USD 1 – 16.25 |
| Volume | 65,876 shares |
| Market Cap | $15.76M |
| Exchange | NCM |
Technical Analysis (RADX)
Nexqual's technical model rates RADX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.54 (oversold) |
| vs SMA50 | Below (USD 1.95) |
| MACD | -0.26 (negative) |
Analyst Ratings (RADX)
Wall Street analysts rate RADX "Buy" based on 5 analysts, with a mean price target of USD 16.95 (range USD 12.41–29.94), per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 16.95 |
| High Target | USD 29.94 |
| Low Target | USD 12.41 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (RADX)
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (RADX)
| Total Revenue | $12.87M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -36.90% |
| Gross Margin | -266.89% |
| Operating Margin | -400.35% |
| Profit Margin | +0.00% |
| ROE | -174.71% |
| Current Ratio | 1.16 |
| Total Cash | $4.14M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (RADX)
Nexqual rates Radiopharm Theranostics Limited's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — AUD 4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -AUD 53M (TTM) |
| Efficiency | Critical — ROE -175%, ROA -45.2% |
Ownership (RADX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.74% |
| Shares Outstanding | 14.59M |
| Float | 11.96M |
| Short % of Float | +0.26% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (RADX)
Radiopharm Theranostics Limited is led by Riccardo Canevari, MD, CEO & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| MD, CEO & Director | Riccardo Canevari |
|---|---|
| Founder & Executive Chairman | Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD (age 69) |
| Chief Financial Officer | Aaron Laurita |
Major Backers & Investors (RADX)
Notable institutional backers of Radiopharm Theranostics Limited include Regal Partners Ltd., PNC Financial Services Group, Inc., according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Regal Partners Ltd. | 0.37% |
| PNC Financial Services Group, Inc. | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| HSBC Holdings PLC | 0.57% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt